MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD). Background: AIM-TD is the second large 12-week, Phase III,…
  • 2017 International Congress

    Improving Nursing Education on the care of those with Parkinson’s disease

    G. Vernon (Philadelphia, PA, USA)

    Objective: The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson's DIsease Foundation provides a 40 contact hour accredited course for nursing faculty by linking…
  • 2017 International Congress

    Ataxia and increased cerebrospinal fluid phosphate associated with a mutation in the SLC20A2 gene

    M. Paucar, H. Almqvist, V. Jelic, G. Hagman, G. Jörneskog, S. Holmin, I. Björkhem, P. Svenningsson (Stockholm, Sweden)

    Objective: To characterize the phenotype and biochemical abnormalities associated with the R467X mutation in the SLCA20A2 gene. Background: Mutations in the SLC20A2 gene are the…
  • 2017 International Congress

    Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation

    C. Fitzer-Attas, D. Stephenson, K. Romero, J. Neville, C. Sampaio (Critical Path Institute, Tucson, AZ; CHDI Foundation, Princeton, NJ)

    Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…
  • 2017 International Congress

    Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.

    P. Fazio, C. Fittzer-Attas, J. Bronzova, S. Nag, J. Warner, B. Landwehrmeyer, N. Al-Tawil, C. Halldin, L. Mrzljak, C. Sampaio, A. Varrone (Stockholm, Sweden)

    Objective: The objective of this study was to examine the loss of Phosphodiesterase 10A enzyme (PDE10A) across a broad spectrum of Huntington’s disease (HD) stages.…
  • 2017 International Congress

    Depression among Inpatients with Huntington’s Disease: Patient Characteristics and Outcomes

    F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

    Objective: To better understand the relationship between Huntington’s Disease and depression. Background: Huntington’s Disease (HD) is an uncommon genetic neurodegenerative disorder in the United States…
  • 2017 International Congress

    The nature of postural tremor in Parkinson’s disease

    M. Dirkx, H. Zach, M. Hallet, R. Helmich (Nijmegen, Netherlands)

    Objective: To identify dopaminergic mechanisms underlying postural tremor in Parkinson's disease.  Background: Parkinson’s tremor classically occurs at rest, but many patients also have a postural…
  • 2017 International Congress

    Characterizing the Bcl-2 Associated Athanogene 5 Interactome

    E. Friesen, X. Wang, D. Williams, H. Chau, M. De Snoo, O. Pellerito, L. Kalia, G. Schmitt-Ulms, S. Kalia (Toronto, ON, Canada)

    Objective: Characterizing the Bcl-2 Associated Athanogene 5 (BAG5) interactome will uncover the molecular pathways with which BAG5 associates and further elucidate its role in dopaminergic…
  • 2017 International Congress

    Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.

    L. Andreoli, C. Alcacer, I. Sebastianutto, A. Cenci Nilsson (Lund, Sweden)

    Objective: We set out to compare movement patterns induced by systemic administration of l-dopa versus D1- or D2-class DA receptor agonists in mice with unilateral…
  • « Previous Page
  • 1
  • …
  • 113
  • 114
  • 115
  • 116
  • 117
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley